These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 2378135)
1. [Value of neopterin as an oncologic laboratory parameter--observations in gynecologic tumors]. von Broen B; Kavungu P Z Gesamte Inn Med; 1990 Apr; 45(8):223-5. PubMed ID: 2378135 [TBL] [Abstract][Full Text] [Related]
2. [Studies of the relevance of the tumor marker neopterin for therapeutic decisions and follow-up of breast cancer]. Hacker I; Lauterbach H; Kob D Radiobiol Radiother (Berl); 1989; 30(6):521-6. PubMed ID: 2608892 [TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196 [TBL] [Abstract][Full Text] [Related]
4. [Experiences with the cancer marker CA 125 in gynecologic diseases]. Pilgrim G; von Broen B; Johannsmeyer KD Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520 [TBL] [Abstract][Full Text] [Related]
5. The significance of neopterin determination as a tumour marker in ovarian cancer. Szarka G; Pulay T; Csömör S; Tran-Phoung-Mai ; Schumann B Acta Chir Hung; 1988; 29(4):359-64. PubMed ID: 3239335 [TBL] [Abstract][Full Text] [Related]
6. [Initial experiences with the determination of neopterin in the urine of females with genital and breast tumors]. Bartel U; Rabe H; Schulz-Pinkus M Zentralbl Gynakol; 1987; 109(20):1226-32. PubMed ID: 3425023 [TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in the diagnosis and prognosis of breast cancer]. Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917 [TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in gynecological and breast cancer]. Jobo T; Sato R; Kuramoto H Rinsho Byori; 2003 Dec; 51(12):1188-94. PubMed ID: 14743742 [TBL] [Abstract][Full Text] [Related]
9. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation. Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728 [TBL] [Abstract][Full Text] [Related]
10. [Tumor markers in breast cancer]. Kurebayashi J Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944 [TBL] [Abstract][Full Text] [Related]
11. On reference values for tumor markers in prostatic carcinoma. Lewenhaupt A; Ekman P; Eneroth P; Kallner A Scand J Urol Nephrol Suppl; 1988; 110():119-23. PubMed ID: 3263693 [TBL] [Abstract][Full Text] [Related]
12. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Jäger W Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443 [No Abstract] [Full Text] [Related]
13. [Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy of metastatic breast cancer]. Kürzl R; Kuss E Geburtshilfe Frauenheilkd; 1993 Aug; 53(8):585-9. PubMed ID: 8375642 [No Abstract] [Full Text] [Related]
14. Neopterin. A tumor marker in colorectal carcinoma? Putzki H; Aschern F; Henkel E; Heymann H Dis Colon Rectum; 1987 Nov; 30(11):879-83. PubMed ID: 3479311 [TBL] [Abstract][Full Text] [Related]
15. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403 [TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of tumor markers in breast cancer]. Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956 [TBL] [Abstract][Full Text] [Related]
17. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243 [TBL] [Abstract][Full Text] [Related]
18. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Jiang XT; Tao HQ; Zou SC Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690 [TBL] [Abstract][Full Text] [Related]
19. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Amoura Z; Duhaut P; Huong DL; Wechsler B; Costedoat-Chalumeau N; Francès C; Cacoub P; Papo T; Cormont S; Touitou Y; Grenier P; Valeyre D; Piette JC Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1279-82. PubMed ID: 15894686 [TBL] [Abstract][Full Text] [Related]
20. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]